Australian Clinical Labs Limited (ASX:ACL)
Australia flag Australia · Delayed Price · Currency is AUD
2.490
-0.020 (-0.80%)
Sep 26, 2025, 4:15 PM AEST
-0.80%
Market Cap484.22M
Revenue (ttm)741.27M
Net Income (ttm)32.43M
Shares Out194.47M
EPS (ttm)0.17
PE Ratio14.60
Forward PE13.06
Dividend0.13 (5.02%)
Ex-Dividend DateSep 1, 2025
Volume416,817
Average Volume796,745
Open2.510
Previous Close2.510
Day's Range2.480 - 2.510
52-Week Range2.460 - 3.860
Beta1.07
RSI40.47
Earnings DateFeb 25, 2026

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. ... [Read more]

Sector Healthcare
Founded 2020
Employees 4,700
Stock Exchange Australian Securities Exchange
Ticker Symbol ACL
Full Company Profile

Financial Performance

In 2025, Australian Clinical Labs's revenue was 741.27 million, an increase of 6.45% compared to the previous year's 696.37 million. Earnings were 32.43 million, an increase of 35.50%.

Financial Statements

News

There is no news available yet.